KeyBanc Reduces its Price Target on Hinge Health, Inc. (HNGE) to $55 and Maintains an Overweight Rating

Core Viewpoint - KeyBanc and other analysts have reduced their price targets for Hinge Health, Inc. while maintaining positive ratings, reflecting a strong Q4 performance and optimistic future guidance despite the price adjustments [1][2][3]. Price Target Adjustments - KeyBanc lowered its price target on Hinge Health to $55 from $70 while maintaining an Overweight rating [1]. - Evercore ISI analyst Elizabeth Anderson reduced the price target to $50 from $65 but kept an Outperform rating, citing strong Q4 revenue and above-street FY26 guidance [2]. - Canaccord cut its price target to $53 from $65 while reiterating a Buy rating, noting a strong Q4 performance and better-than-expected outlook for 1Q'26 and the full year [2]. Financial Performance - Hinge Health reported Q4 revenue of $170.7 million, exceeding the consensus estimate of $156.8 million [3]. - Co-Founder and CEO Daniel Perez highlighted strong win rates and a record number of eligible lives added, indicating commercial momentum and expanding margins [3]. Business Model and Strategy - Hinge Health focuses on scaling and automating healthcare delivery through an AI-powered care model, wearable devices, and clinician access to provide evidence-based services for musculoskeletal conditions [4].